Clinical trial
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium…
NCT03532009 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT03532009 |
|---|---|
| Title | Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure |
| Official title | A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure |
| Acronym | PRIORITIZE HF |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | Sodium Zirconium Cyclosilicate, Placebo |
| Enrollment | 182 |
| Start date | Jun 26, 2018 |
| Primary completion | May 22, 2020 |
| Completion | May 22, 2020 |
| First posted | May 22, 2018 |
| Last update posted | Jun 15, 2021 |
| Countries | Brazil, Bulgaria, Canada, Hungary, Poland, Romania, Russia, Slovakia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: